Among Black patients with suppressed HIV, estimated glomerular filtration rate by cystatin C appears to provide clinically ...

Updated recommendations were issued by the IAS-USA regarding the use of ART for treatment and prevention of HIV in adult populations.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced that the European Commission has authorised Vocabria (cabotegravir ...

在格拉斯哥举行的HIV药物治疗会议上，一份病例报告显示， 一名接受具有罕见突变（该突变可阻止病毒进入细胞）的供体干细胞移植以治疗癌症的患者，可能成为 第八例长期病毒缓解的HIV感染者。

第一个成功的治愈案例是蒂莫西·雷·布朗，被称为“柏林患者”。2006年，他因急性髓性白血病接受了两次干细胞移植。柏林查理特医院的肿瘤学专家Gero Hütter博士提出使用带有CCR5-delta32突变的供体干细胞，这种突变可以阻止大多数HIV病毒进入细胞。